Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
COA on request
- Arrives Thu, Oct 22 – Tue, Oct 27Free standard shipping on orders over $100
- Free shipment protectionLost, stolen, or damaged? We replace it, on us.
- Overnight and 2-day optionsPick your speed at checkout
GLP-1 (SM)
Metabolic Research Peptide
A 31-residue, fatty-acid-modified analog of glucagon-like peptide-1 with an extended half-life. It is used in metabolic research on GLP-1 receptor signaling, insulin secretion, gastric emptying and appetite regulation. For in vitro laboratory research use only.
- Arrives Thu, Oct 22 – Tue, Oct 27Free standard shipping on orders over $100
- Free shipment protectionLost, stolen, or damaged? We replace it, on us.
- Overnight and 2-day optionsPick your speed at checkout
Compound Information
What is GLP-1 (SM)?
- CAS number
- 910463-68-2
- Molecular weight
- 4,113.58 g/mol
- Amino acids
- 31
- Formula
- C187H291N45O59
- Sequence
- 31-residue GLP-1(7-37) analog; Aib8 and Arg34 substitutions; C18 diacid on Lys26 via gamma-Glu + 2x AEEA
Stability information
- Protect from light
- Avoid repeated freeze-thaw cycles
Conditions apply to sealed research vials as supplied. Batch details are on the Certificate of Analysis above.
Sources & References
Peer-reviewed research
Once-Weekly Semaglutide in Adults with Overweight or Obesity
View Source ↗Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
View Source ↗The Discovery and Development of Liraglutide and Semaglutide
View Source ↗Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
View Source ↗Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
View Source ↗Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
View Source ↗A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
View Source ↗Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
View Source ↗Frequently Researched Together
Related research compounds
Cagrilintide
Long-acting amylin analog
GLP-2 (TR)
Metabolic Research Peptide
MOTS-C
Mitochondrial-derived peptide
GLP-3 (RT)
Triple-agonist metabolic research peptide
AHK-Cu
Copper Peptide
SELANK
Anxiolytic research peptide
5-Amino-1MQ
Metabolic Peptide
Glutathione
Antioxidant & Detoxification Peptide
ARA-290
Cellular Peptide